Yep. Looks like an open market buy as opposed to Options Exercised.
Real nice. Undeniably positive event...and dare I say, bullish?
Will be even better if we see a slew of other open market buys as we are now, obviously, in the period for Insiders to buy, etc.
This is great. Would love to see more insider buys. Also, would be nice to hear comments/updates from all the analysts covering this. Up $2.00 in 2 days takes a little of the sting away, but would love to see $18 again.
I suspect some of the board might follow. The market and the analysts will respond positively. Assuming we are in-market selling by Q4 of next year they should move up the timeline for revenue and run a discounted cash flow model. If, in fact, aggregate European/Asian/African cases are what has been posted close to 10,000 cases of NTM should be revenue generating (around 10% of afflicted).. At $16,000 per 12 week dosing and an average of 26 weeks on the program it amounts to $320 million in revenues. Add in Arikace being added to the CF regimen in Europe and we're looking at between $400 and $500 million in sales through july 1, 2015 and over $1 billion in all of 2015. This generates a valuation of between $5 billion and $6 billion, discounted by 20% or between $4 billion and $4.8 billion or as much as $100/share on the discounted cash flow model and 48 million shares. Here's hoping.
another good sign ..... raising money is going well. Balance sheet looking healthy. Regulatory path is clearer than ever. Two consecutive UP days ..... Feeling better about seeing $19 and $20 again sooner rather than later.